See What HealthDay Can Do For You
Contact Us

Weight Not a Factor in Sirolimus-Eluting Stent Outcomes

Overweight and obese patients do not have a higher incidence of major adverse events, study suggests

MONDAY, June 16 (HealthDay News) -- In patients with multivessel coronary artery disease who are treated with sirolimus-eluting stents, body mass index has no effect on short-term outcomes, according to the results of a study published in the June issue of the American Journal of Cardiology.

Ahmed A. Khattab, M.D., of Segeberger Kliniken GmbH in Bad Segeberg, Germany, and colleagues compared outcomes in 607 patients with multivessel coronary artery disease, including 176 who were normal-weight, 289 who were overweight and 142 who were obese.

After 30 days, the researchers found that the cumulative incidence of death, myocardial infarction, cerebrovascular accident and repeat revascularization was similar for normal-weight, overweight and obese patients (3.4 percent, 3.1 percent and 2.8 percent, respectively). After one year, they found that the cumulative incidence of major adverse cardiac and cerebrovascular events in the normal-weight, overweight and obese subjects was 10.8 percent, 11.8 percent and 7 percent, respectively.

"It should be noted that the number of patients in each group was relatively small, resulting in a small number of adverse events," the authors state. "By its retrospective design, the present study may have suffered from a lack of power to detect statistically significant differences among the groups. Larger randomized controlled trials are needed to validate our findings."

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.